Abstract
Genes coding for proteins involved in steroid hormone signaling have been identified as ovarian cancer risk-modifier candidates. AIB1 gene (amplified in breast cancer-1), an androgen receptor (AR) coactivator, expresses a polyglutamine (poly-Q) sequence within the carboxyl-terminal coding region. We hypothesized that genotypic variations in the androgen-signaling pathway promote aggressive epithelial ovarian cancer biology and sought to examine the effect of AIB1 poly-Q repeat length on ovarian cancer risk with a case–control study. The genotype analysis of the AIB1 poly-Q repeat was conducted in 3,000 epithelial ovarian cancer (EOC) cases and 3,000 healthy controls. When analyzed as a categorical variable with cutoff of <28 or <29, both of results showed significant asociations. Compared to those with the shorter (<29) AIB1 poly-Q repeat length, women in the category of longer (≥29) poly-Q repeats had a significantly 20 % increased EOC risk (odds ratio (OR) = 1.20; 95 % confidence interval (CI), 1.08–1.33; P = 5.88 × 10−4). When analyzed as a continuous covariate, women with longer average poly-Q repeat length had a significantly increased risk of developing EOC (OR = 1.05 for per poly-Q repeat; 95 % CI, 1.00–1.08; P = 0.013). The association was more stronger for per longer allele (OR = 1.07; 95 % CI, 1.01–1.12; P = 0.010). These results strongly suggest that there is a significant effect of AIB1 genetic variation on ovarian cancer risk, and AIB1 underlies the development of ovarian cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Cl Ob. 2006;20:207–25.
Jemal A, Siegel R, Xu JQ, Ward E. Cancer statistics, 2010. Ca-Cancer J Clin. 2010;60:277–300.
DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–71.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
Otani Y, Miyake T, Kagara N, Shimoda M, Naoi Y, Maruyama N, Shimomura A, Shimazu K, Kim SJ, Noguchi S: BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer. Cancer Sci 2014
Paul BT, Blanchard Z, Ridgway M, ElShamy WM: BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin. Oncogene 2014
Janavicius R, Rudaitis V, Mickys U, Elsakov P, Griskevicius L. Comprehensive BRCA1 and BRCA2 mutational profile in Lithuania. Cancer Genet. 2014;207:195–205.
Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science. 1997;277:965–8.
Han XY, Chen Y, Hou MM, Zhang J, Yang KX, Chen YY, et al. [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis]. Sichuan da xue xue bao Yi xue ban. J Sichuan Univ Med Sci Ed. 2008;39:619–22. 634.
Li AJ, Lerner DL, Gapuzan ME, Karlan BY. AIB1 polymorphisms predict aggressive ovarian cancer phenotype. Cancer Epidemiol Biomark Prev. 2005;14:2919–22.
Permuth-Wey J, Sellers TA. Epidemiology of ovarian cancer. Methods Mol Biol. 2009;472:413–37.
Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008;198(459):e451–8. discussion 459 e458-459.
Schildkraut JM, Murphy SK, Palmieri RT, Iversen E, Moorman PG, Huang Z, et al. Trinucleotide repeat polymorphisms in the androgen receptor gene and risk of ovarian cancer. Cancer Epidemiol Biomark Prev. 2007;16:473–80.
Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res. 2005;65:5974–81.
Terry KL, De Vivo I, Titus-Ernstoff L, Sluss PM, Cramer DW. Genetic variation in the progesterone receptor gene and ovarian cancer risk. Am J Epidemiol. 2005;161:442–51.
Ying H, Lyu J, Ying T, Li J, Jin S, Shao J, et al. Risk miRNA screening of ovarian cancer based on mirna functional synergistic network. J Ovarian Res. 2014;7:9.
Shirazi SK, Bober MA, Coetzee GA. Polymorphic exonic cag microsatellites in the gene amplified in breast cancer (AIB1 gene). Clin Genet. 1998;54:102–3.
Kleibl Z, Havranek O, Kormunda S, Novotny J, Foretova L, Machackova E, et al. The AIB1 gene polyglutamine repeat length polymorphism and the risk of breast cancer development. J Cancer Res Clin Oncol. 2011;137:331–8.
Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001;61:5420–4.
Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med (Berl). 2006;84:16–28.
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, et al. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res. 2000;6:1833–9.
Acknowledgments
We thank all the staff who were involved in the subject recruitment, telephone interviews, sample preparation, and laboratory assays for their hard works.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.
An erratum to this article is available at http://dx.doi.org/10.1007/s13277-017-5487-6.
About this article
Cite this article
Han, G., Xie, S., Fang, H. et al. RETRACTED ARTICLE: The AIB1 gene polyglutamine repeat length polymorphism contributes to risk of epithelial ovarian cancer risk: a case–control study. Tumor Biol. 36, 371–374 (2015). https://doi.org/10.1007/s13277-014-2661-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-2661-y